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SUPPLEMENTARY MATERIALS AND METHODS 
 
Cell culture and transfection 
Human embryonic kidney (HEK) cell line 293FT (Life Technologies) was maintained in 
Dulbecco’s modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum 
(HyClone), 2mM GlutaMAX (Life Technologies), 100U/mL penicillin, and 100µg/mL 
streptomycin at 37ºC with 5% CO2 incubation. Mouse neuro2A (N2A) cell line (ATCC) was 
maintained with DMEM supplemented with 5% fetal bovine serum (HyClone), 2mM GlutaMAX 
(Life Technologies), 100U/mL penicillin, and 100µg/mL streptomycin at 37ºC with 5% CO2. 
 
293FT or N2A cells were seeded into 24-well plates (Corning) one day prior to transfection at a 
density of 200,000 cells per well. Cells were transfected using Lipofectamine 2000 (Life 
Technologies) following the manufacturer’s recommended protocol. For each well of a 24-well 
plate a total of 800ng plasmids was used. 
 
Suveryor assay and sequencing analysis for genome modification 
293FT or N2A cells were transfected with plasmid DNA as described above. Cells were 
incubated at 37ºC for 72 hours post transfection before genomic DNA extraction. Genomic DNA 
was extracted using the QuickExtract DNA extraction kit (Epicentre) following the 
manufacturer’s protocol. Briefly, cells were resuspended in QuickExtract solution and incubated 
at 65ºC for 15 minutes and 98ºC for 10 minutes. 
 
Genomic region surrounding the CRISPR target site for each gene was PCR amplified, and 
products were purified using QiaQuick Spin Column (Qiagen) following manufacturer’s 
protocol. A total of 400ng of the purified PCR products were mixed with 2µl 10X Taq 
polymerase PCR buffer (Enzymatics) and ultrapure water to a final volume of 20µl, and 
subjected to a re-annealing process to enable heteroduplex formation: 95ºC for 10min, 95ºC to 
85ºC ramping at – 2ºC/s, 85ºC to 25ºC at – 0.25ºC/s, and 25ºC hold for 1 minute. After re-
annealing, products were treated with SURVEYOR nuclease and SURVEYOR enhancer S 
(Transgenomics) following the manufacturer’s recommended protocol, and analyzed on 4-20% 
Novex TBE poly-acrylamide gels (Life Technologies). Gels were stained with SYBR Gold DNA 
stain (Life Technologies) for 30 minutes and imaged with a Gel Doc gel imaging system (Bio-
rad). Quantification was based on relative band intensities.  
 
Restriction fragment length polymorphism assay for detection of homologous recombination 
HEK 293FT and N2A cells were transfected with plasmid DNA, and incubated at 37°C for 72 
hours before genomic DNA extraction as described above. The target genomic region was PCR 
amplified using primers outside the homology arms of the homologous recombination (HR) 
template. PCR products were separated on a 1% agarose gel and extracted with MinElute 
GelExtraction Kit (Qiagen). Purified products were digested with HindIII (Fermentas) and 
analyzed on a 6% Novex TBE poly-acrylamide gel (Life Technologies). 
 
RNA extraction and purification 
HEK 293FT cells were maintained and transfected as stated previously. Cells were harvested by 
trypsinization followed by washing in phosphate buffered saline (PBS). Total cell RNA was 
extracted with TRI reagent (Sigma) following manufacturer’s protocol. Extracted total RNA was 
quantified using Naonodrop (Thermo Scientific) and normalized to same concentration. 
 
Northern blot analysis of crRNA and tracrRNA expression in mammalian cells 
RNAs were mixed with equal volumes of 2X loading buffer (Ambion), heated to 95ºC for 5 min, 
chilled on ice for 1 min and then loaded onto 8% denaturing polyacrylamide gels (SequaGel, 
National Diagnostics) after pre-running the gel for at least 30 minutes. The samples were 
electrophoresed for 1.5 hours at 40W limit. Afterwards, the RNA was transferred to Hybond N+ 
membrane (GE Healthcare) at 300 mA in a semi-dry transfer apparatus (Bio-rad) at room 
temperature for 1.5 hours. The RNA was crosslinked to the membrane using autocrosslink button 
on Stratagene UV Crosslinker the Stratalinker (Stratagene). The membrane was pre-hybridized 
in ULTRAhyb-Oligo Hybridization Buffer (Ambion) for 30 min with rotation at 42ºC and then 
probes were added and hybridized overnight. Probes were ordered from IDT and labeled with 
[gamma-32P] ATP (Perkin Elmer) with T4 polynucleotide kinase (New England Biolabs). The 
membrane was washed once with pre-warmed (42ºC) 2xSSC, 0.5% SDS for 1 min followed by 
two 30 minute washes at 42ºC. The membrane was exposed to phosphor screen for one hour or 





Fig. S1. Schematic of the type II CRISPR-mediated DNA double-strand break. The type II 
CRISPR locus from Streptococcus pyogenes SF370 contains a cluster of four genes, Cas9, Cas1, 
Cas2, and Csn1, as well as two non-coding RNA elements, tracrRNA and a characteristic array 
of repetitive sequences (direct repeats) interspaced by short stretches of non-repetitive sequences 
(spacers, 30bp each) (15-18, 30, 31). Each spacer is typically derived from foreign genetic 
material (protospacer), and directs the specificity of CRISPR-mediated nucleic acid cleavage. In 
the target nucleic acid, each protospacer is associated with a protospacer adjacent motif (PAM) 
whose recognition is specific to individual CRISPR systems (22, 23). The Type II CRISPR 
system carries out targeted DNA double-strand break (DSB) in sequential steps (12-14, 20, 21). 
First, the pre-crRNA array and tracrRNA are transcribed from the CRISPR locus. Second, 
tracrRNA hybridizes to the direct repeats of pre-crRNA and associates with Cas9 as a duplex, 
which mediates the processing of the pre-crRNA into mature crRNAs containing individual, 
truncated spacer sequences. Third, the mature crRNA:tracrRNA duplex directs Cas9 to the DNA 
target consisting of the protospacer and the requisite PAM via heteroduplex formation between 
the spacer region of the crRNA and the protospacer DNA. Finally, Cas9 mediates cleavage of 




















Streptococcus pyogenes SF370 type II CRISPR locus
Figure S2 
 
Fig S2. Comparison of different tracrRNA transcripts for Cas9-mediated gene targeting. 
(A) Schematic showing the design and sequences of two tracrRNA transcripts tested (short and 
long). Each transcript is driven by a U6 promoter. Transcription start site is marked as +1 and 
transcription terminator is as indicated. Blue line indicates the region whose reverse-complement 
sequence is used to generate northern blot probes for tracrRNA detection. (B) SURVEYOR 
assay comparing the efficiency of SpCas9-mediated cleavage of the EMX1 locus. Two biological 
replicas are shown for each tracrRNA transcript. (C) Northern blot analysis of total RNA 
extracted from 293FT cells transfected with U6 expression constructs carrying long or short 
tracrRNA, as well as SpCas9 and DR-EMX1(1)-DR. Left and right panels are from 293FT cells 
transfected without or with SpRNase III respectively. U6 indicate loading control blotted with a 
probe targeting human U6 snRNA. Transfection of the short tracrRNA expression construct led 
to abundant levels of the processed form of tracrRNA (~75bp) (19). Very low amounts of long 
tracrRNA are detected on the northern blot. As a result of these experiments, we chose to use 
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Fig. S3. SURVEYOR assay for detection of double strand break-induced micro insertions 
and deletions (32). Schematic of the SURVEYOR assay used to determine Cas9-mediated 
cleavage efficiency. First, genomic PCR (gPCR) is used to amplify the Cas9 target region from a 
heterogeneous population of modified and unmodified cells, and the gPCR products are 
reannealed slowly to generate heteroduplexes. The reannealed heteroduplexes are cleaved by 
SURVEYOR nuclease, whereas homoduplexes are left intact. Cas9-mediated cleavage efficiency 
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Fig. S4. Northern blot analysis of crRNA processing in mammalian cells. (A) Schematic 
showing the expression vector for a single spacer flanked by two direct repeats (DR-EMX1(1)-
DR). The 30bp spacer targeting the human EMX1 locus protospacer 1 (Table S1) is shown in 
blue and direct repeats are in shown in gray. Orange line indicates the region whose reverse-
complement sequence is used to generate northern blot probes for EMX1(1) crRNA detection. 
(B) Northern blot analysis of total RNA extracted from 293FT cells transfected with U6 
expression constructs carrying DR-EMX1(1)-DR. Left and right panels are from 293FT cells 
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mature crRNAs only in the presence of SpCas9 and short tracrRNA, and was not dependent on 
the presence of SpRNase III. The mature crRNA detected from transfected 293FT total RNA is 
~33bp and is shorter than the 39-42bp mature crRNA from S. pyogenes (19), suggesting that the 
processed mature crRNA in human 293FT cells is likely different from the bacterial mature 





Fig. S5. Bicistronic expression vectors for pre-crRNA array or chimeric crRNA with Cas9. 
(A) Schematic showing the design of an expression vector for the pre-crRNA array. Spacers can 
be inserted between two BbsI sites using annealed oligonucleotides. Sequence design for the 
oligonucleotides are shown below with the appropriate ligation adapters indicated. (B) Schematic 
of the expression vector for chimeric crRNA. The guide sequence can be inserted between two 
BbsI sites using annealed oligonucleotides. The vector already contains the partial direct repeat 
(gray) and partial tracrRNA (red) sequences. WPRE, Woodchuck hepatitis virus post-
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3’-..CCCAAAATCTCGATACGACAAAACTTACCAGGGTTTTGCCCAGAAGCTCTTCTGCAAAATCTCGATACGACAAAACTTACCAGGGTTTTGAAAAA..-5’
5’- CACCGNNNNNNNNNNNNNNNNNNN -3’
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Fig. S6. Selection of protospacers in the human PVALB and mouse Th loci. Schematic of the 
human PVALB (A) and mouse Th (B) loci and the location of the three protospacers within the 
last exon of the PVALB and Th genes, respectively. The 30bp protospacers are indicated by black 
lines and the adjacent PAM sequences are indicated by the magenta bar. Protospacers on the 
























     |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
     AGTTCCCAGCCCCTTCTCCAACCTTTCCTGGCCCAGAGGCTTTCCCATGTGTGTGGCTGGACCCTTTGA..3’












Fig. S7. Occurrences of PAM sequences in the human genome. Histograms of distances 
between adjacent Streptococcus pyogenes SF370 type II CRISPR PAM (NGG) (A) and 
Streptococcus thermophiles LMD-9 CRISPR1 PAM (NNAGAAW) (B) in the human genome. 
(C) Distances for each PAM by chromosome. Chr, chromosome. Putative targets were identified 
using both the plus and minus strands of human chromosomal sequences. Given that there may 
be chromatin, DNA methylation-, RNA structure, and other factors that may limit the cleavage 
activity at some protospacer targets, it is important to note that the actual targeting ability might 
be less than the result of this computational analysis. 
 
 













Streptococcus pyogenes SF370 type II CRISPR 















Streptococcus thermophilus LMD-9 CRISPR1 
PAM occurence in human genome (NNAGAAW)




Chr median mean median mean
1 7 12.8 67 115.8
2 8 12.7 64 100.8
3 8 13.0 63 98.5
4 9 14.0 61 94.5
5 8 13.1 63 97.9
6 8 13.1 63 98.5
7 8 12.4 64 102.9
8 8 12.8 64 100.9
9 7 13.9 65 120.5
10 7 12.1 66 107.0
11 7 12.0 65 105.8
12 8 12.4 65 103.5
13 8 13.6 62 94.6
14 8 12.0 65 101.5
15 7 11.5 68 107.7
16 7 11.7 74 136.8
17 6 10.3 76 127.9
18 8 13.4 63 101.8
19 6 9.4 82 145.4
20 7 11.1 72 121.8
21 7 13.4 64 111.4
22 6 9.2 85 140.3
NGG NNAGAAW
Y 8 29.2 62 223.7







Fig S8. Type II CRISPR from Streptococcus thermophilus LMD-9 can also function in 
eukaryotic cells. (A) Schematic of CRISPR locus 2 from Streptococcus thermophilus LMD-9. 
(B) Design of the expression system for the S. thermphilus CRISPR system. Human codon-
optimized StCas9 is expressed using a constitutive EF1a promoter. Mature versions of tracrRNA 
and crRNA are expressed using the U6 promoter to ensure precise transcription initiation. 
Sequences for the mature crRNA and tracrRNA are shown. A single based indicated by the 
lower case “a” in the crRNA sequence was used to remove the polyU sequence, which serves as 
a RNA Pol III transcriptional terminator. Sp, spacer. (C) Schematic showing protospacer and 
A
C
StCas9 Cas1 Cas2 Csn2
direct repeats
spacerSt-tracrRNA
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     ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3’-..AAAAGATCACGACTCAAAGACACTGAGGAGATGTAAGATGAAGAGACACAAAGACATATGATGGAGGAGG..-5’
protospacer (16) protospacer (15)PAM PAM
corresponding PAM sequences targets in the human EMX1 locus. Two protospacer sequences 
are highlighted and their corresponding PAM sequences satisfying the NNAGAAW motif are 
indicated by magenta lines. Both protospacers are targeting the anti-sense strand. (D) 
SURVEYOR assay showing StCas9-mediated cleavage in the target locus. RNA guide spacers 1 
and 2 induced 14% and 6.4% respectively. Statistical analysis of cleavage activity across 
biological replica at these two protospacer sites can be found in Table S1. 
 
  
Table S1. Protospacer sequences and modification efficiencies of mammalian genomic 
targets. Protospacer targets designed based on Streptococcus pyogenes type II CRISPR and 
Streptococcus thermophilus CRISPR1 loci with their requisite PAMs against three different 
genes in human and mouse genomes. Cells were transfected with Cas9 and either pre-
crRNA/tracrRNA or chimeric RNA. Cells were analyzed 72 hours after transfection. Percent 
indels are calculated based on SURVEYOR assay results from indicated cell lines, N = 3 for all 
protospacer targets, errors are S.E.M. N.D., not detectable using the SURVEYOR assay; N.T., 























PVALB ATGCAGGAGGGTGGCGAGAGGGGCCGAGAT TGG + 293FT
Th CAAGCACTGAGTGCCATTAGCTAAATGCAT AGG – Neuro2A
Th AATGCATAGGGTACCACCCACAGGTGCCAG GGG – Neuro2A































CATCGATGTCCTCCCCATTGGCCTGCTTCG TGGEMX1 – 293FT 11 ± 1.7
TTCGTGGCAATGCGCCACCGGTTGATGTGA TGGEMX1 – 293FT 4.3 ± 0.46
TCGTGGCAATGCGCCACCGGTTGATGTGAT GGGEMX1 – 293FT 4.0 ± 0.66











































Table S2. Sequences for primers and probes used for SURVEYOR assay, RFLP assay, 
genomic sequencing, and Northern blot. 
 



























































































































































































> 3xFLAG-NLS-SpCas9n-NLS (the D10A nickase mutation is labeled 
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